InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital assumed coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target for the company.

InspireMD Trading Up 1.1 %

NSPR stock opened at $2.84 on Monday. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.80. The company has a market capitalization of $74.08 million, a P/E ratio of -3.79 and a beta of 0.88. The firm has a 50 day simple moving average of $2.84 and a 200-day simple moving average of $2.76.

Hedge Funds Weigh In On InspireMD

Several large investors have recently added to or reduced their stakes in NSPR. Renaissance Technologies LLC bought a new position in InspireMD during the fourth quarter worth $27,000. Legato Capital Management LLC bought a new position in InspireMD during the fourth quarter worth $47,000. Schonfeld Strategic Advisors LLC lifted its stake in InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after purchasing an additional 18,233 shares during the last quarter. Northern Trust Corp lifted its stake in InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after purchasing an additional 24,452 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in InspireMD during the fourth quarter worth $191,000. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.